A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours

Summary

This is the first in human study of BL0006, and the primary objective is to evaluate the safety and tolerability of BL0006 as a single agent in patients with advanced solid tumors.

Timeline

Start

2024-01-03

Primary completion

2024-10

Completion

2025-05

Drugs

Indications